Unlocking drug delivery to the brain.
The biggest challenge in treating brain diseases today isn’t finding good drugs – it’s getting them where they need to go.
THE BRAIN IS MEDICINE'S GREATEST FRONTIER
Brain-related conditions are the second leading cause of death and the leading cause of disability worldwide. Yet the therapeutic arsenal remains remarkably limited, not because effective drugs don’t exist, but because the blood-brain barrier (BBB) physically prevents them from reaching their target. Antibodies and oligonucleotide therapeutics, the fastest-growing and most promising drug modalities in medicine today, are almost entirely blocked by the BBB. The drugs exist. The delivery doesn’t.
98% of drugs cannot cross the blood-brain barrier
Some of the most promising treatments in medicine today cannot reach the patients who need them most.
Learn how our BrainPortal™ works →
NUCLEOTECH IS CHANGING THIS
We engineer BrainPortal™ carriers, proteins that attach to therapeutic antibodies and oligonucleotides and carry them across the blood-brain barrier safely and non-invasively. Where promising treatments have been blocked by the BBB, BrainPortal™ carriers give them a path to the brain without surgery, without reformulation, and without starting from scratch.
Our proprietary direct in vivo Technology → makes this possible at a speed and scale the industry has never seen before. It powers our Therapeutic Pipeline →, where we deploy these carriers to advance promising CNS therapeutics internally, and our Carrier Program →, a growing portfolio of proprietary BrainPortal™ carriers available for licensing to pharma and biotech partners.
A BETTER WAY TO BUILD CARRIERS
The industry’s standard approach to brain shuttle discovery tests one carrier at a time, a slow, linear process where each experiment takes months, and progress is measured in years. NucleoTech’s direct in vivo screening platform tests many carriers simultaneously in living animals, with precise and sensitive readouts delivered in days. The result: rapid iteration across hundreds of candidates, best-in-class carriers identified faster, and a compounding development advantage that grows with every cycle.
100x higher throughput than conventional brain shuttle discovery.
Many carriers tested simultaneously. Precise, sensitive readouts in days. Best-in-class results in months, not years.
Learn more about our Technology →Explore the Platform
Discover the technology, carrier portfolio, and therapeutic programs driving NucleoTech forward.
These shuttles are protein add-ons that give existing drugs the ability to reach the brain – and treat conditions long considered untreatable. We build these – BrainPortal™ shuttles using a unique direct in vivo discovery engine.